Preferred Label : (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;
MeSH note : structure in first source;
CISMeF synonym : LX4211;
MeSH synonym : sotagliflozin;
MeSH hyponym : LX-4211;
Is substance : O;
UNII : 6B4ZBS263Y;
Origin ID : C575681;
UMLS CUI : C3502471;
ATC code(s)
Currated CISMeF NLP mapping
MeSH indexing information
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.ema.europa.eu/en/medicines/human/EPAR/zynquista
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
diabetes mellitus, type 1
adult
drug therapy, combination
insulin
administration, oral
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose transporter 1
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
sotagliflozin
glycosides
glycosides
---